Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2006 Dec 22;1(8):e41.
doi: 10.1371/journal.pctr.0010041.

The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen

John C S Breitner, Barbara K Martin, Curtis L Meinert
Comment

The suspension of treatments in ADAPT: concerns beyond the cardiovascular safety of celecoxib or naproxen

John C S Breitner et al. PLoS Clin Trials. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing Interests: Barbara Martin, Denis Evans, and Curtis L. Meinert have no competing interests to report. John C. S. Breitner previously held partial royalty interests in two United States patents for the use of NSAIDs for the prevention of Alzheimer disease; in January 2005 he assigned these interests irrevocably as a gift to a private charitable foundation in which he has no constructive or beneficial interest.

Comment on

References

    1. Nissen SE. ADAPT: The wrong way to stop a clinical trial. PLoS Clin Trials. 2006;1:e35. doi: 10.1371/journal.pctr.0010035. - DOI - PMC - PubMed
    1. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) PLoS Clin Trials. 2006;1:e33. doi: 10.1371/journal.pctr.0010033. - DOI - PMC - PubMed
    1. Pfizer Investor News Release. Pfizer statement on new information regarding cardiovascular safety of Celebrex. 2004. Available: http://www.pfizer.com/pfizer/are/investors_releases/2004pr/mn_2004_1217.jsp. Accessed 21 November 2006.
    1. Statement from the Steering Committee of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) for communication to the FDA Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee, 18 February 2005. Available: http://www.jhucct.com/adapt/pdf%20documents/FDA%20ADAPT%20STATEMENT_web%.... Accessed 21 November 2006.